Pharmacoeconomic Role Of Clinical Pharmacists: Impact Of Dose Rounding Of Cancer Therapy On Cost Avoidance | 23484
Clinical Pharmacology & Biopharmaceutics
Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.
Background: A significant and progressive cost rising in medical oncology due to the incorporation of novel and highly
expensive drugs into clinical practice have been seen in the past ten years. Dose rounding is an option might be used in oncology
settings to avoid extra cost. The purpose of this project is to determine the theoretical cost saving related to a dose rounding
process for biological and chemotherapy agents in adult oncology settings and to determine the opinion of oncologists about
Materials and methods: Data was obtained prospectively during April 2011. All chemotherapy and targeted therapy orders
prescribed in adult oncology outpatient clinics as well as in-patient wards have been collected. It wasconsidered rounding to
an amount within 15% for targeted therapy and 10% for cytotoxic drugs. Chemotherapy dosing was calculated according to
body surface area. Prescriptions that include cancer therapy in doses that might be rounded according to study criteria were
Results: Two hundred and thirty three orders of chemotherapy and targeted therapy were processed by Adult Oncology
Satellite Pharmacy during the period of data collection. Forty percent of the collected prescriptions fulfilled the criteria. The
potential cost savings from dose rounding per year was $192,800. Data was extrapolated from the determined monthly cost
savings. The highest cost saving was for breast cancer orders $80,820 (42%), followed by colorectal cancer $47,965 (25%), while
in non-Hodgkin's lymphoma cost savings was $ 45,107 (23%) and for other types of cancer that include non small cell lung
cancer, prostate and ovarian cancer, in addition to head and neck cost savings was $18,867 (10%).
Conclusions: The experience confirms the significant cost savings of cancer therapy by applying dose rounding to chemotherapy
and biologic drugs prescriptions. While clinical impact of the suggested percentage needs to be evaluated.
Nagwa Ibrahim is a clinical pharmacist specialized in oncology at Prince Sultan Military Medical City, and adjunct clinical assistant professor at King Saud University
& Princes Nora University, Riyadh Saudi Arabia. She received her Bachelor degree in pharmaceutical science from King Saud University, Saudi Arabia and her
Doctor of Pharmacy degree from Duquesne University,USA. She has outstanding records of scientific and academic accomplishments with numerous publications
in prestigious journals and various active participations in national and international conferences and societies.
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals